Γδ CAR t-cellular vaccine for solid cancers
Luminary Therapeutics presents an innovative γδ T-cell-based CAR T-cell therapy, DACART, designed to target solid tumors. This dual-action therapy combines direct cytotoxic effects with immune system activation to enhance anti-tumor responses.
Overview
Luminary Therapeutics introduces an advanced therapeutic solution for solid tumors through its γδ CAR T-cell-based approach, known as DACART. This dual-action therapy is engineered to target mesothelin-positive tumor cells while simultaneously activating the body's own immune system. By combining direct cytotoxic action with antigen presentation capabilities, DACART aims to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment, leading to sustained and potent anti-tumor responses.
Technical specifications
Key features:
- Dual-action capability: DACART cells are engineered to perform both direct cytotoxic functions and antigen presentation.
- Targeting mesothelin-positive cells: The therapy is specifically designed to attack mesothelin+ tumor cells.
- Enhanced immune activation: Equipped with tandem minigene constructs encoding multiple neoantigens, DACART cells recruit and activate endogenous CD4+ and CD8+ T cells.
- Overcoming tumor heterogeneity: By activating a diverse range of T cell receptor repertoires, DACART addresses the variability within tumor cell populations.
Technology readiness level
DACART has reached a Technology Readiness Level of 3. Current validation efforts include in vitro testing for MSLN-specific cytotoxicity and antigen presentation, as well as in vivo efficacy assessments using humanized mouse models. These efforts are designed to evaluate tumor regression, immune activation, and the therapy's ability to overcome the immunosuppressive tumor microenvironment.
About Luminary Therapeutics
Luminary Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic cell therapies to address limitations in current CAR-T treatments, such as high costs, manufacturing delays, antigen escape, and poor tumor infiltration. The company utilizes its proprietary Gamma 2.0+ platform, which features a non-viral gene modification process known as TcBuster for efficient DNA cargo delivery. Their technology incorporates a stealth immune-cloaking capability to evade T and NK cell clearance without nuclease editing, and employs sophisticated CAR architectures—including dual-targeting designs and ligand-based receptors—to improve persistence, durability, and multi-antigen targeting within the solid tumor microenvironment and against hematological malignancies.
By focusing on off-the-shelf, allogeneic solutions, Luminary aims to increase accessibility, reduce wait times, and improve the cost-effectiveness of cell therapies for patients. Their pipeline targets diverse conditions including Non-Hodgkin Lymphoma, multiple myeloma, and various solid tumors like renal and lung cancers, while also expanding into autoimmune disorders such as lupus. By optimizing co-stimulation domains and leveraging large-cargo capacity, the company seeks to provide more durable responses and overcome the challenges of tumor heterogeneity and immunosuppression, offering a potential path to standardized, scalable, and affordable precision medicine.
delivered to your inbox.